Compare BridgeBio Pharma Inc (BBIO) vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF (SJNK) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BridgeBio Pharma Inc vs State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF — how do they compare? BridgeBio Pharma Inc trades at $84.22 (market cap $16.36B), while State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF trades at $24.87. The key difference: BridgeBio Pharma Inc is trading nearer its 52-week high, State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF nearer its low. Which is the better fit depends on your goals.
| BBIO | SJNK | |
|---|---|---|
Market Cap | $16.36B | — |
Sector | Health | Sector/Thematic |
52-Week High | $90.17 | $25.63 |
52-Week Low | $47.29 | $24.75 |
Enterprise Value | $18.14B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BridgeBio Pharma (BBIO) trades at $84.57, down slightly by 0.12% on the day, with a bullish technical signal from moving averages but mixed oscillators. The company reported Q2 2026 revenue growth driven by Attruby sales, though it missed EPS estimates. With a high P/S ratio of 22.77 and negative profitability metrics, the stock is priced for future growth, supported by strong analyst buy ratings and a $104.56 consensus price target.
The outlook hinges on successful product launches and regulatory approvals, with three potential launches expected within 12 months offering significant upside. Key risks include persistent cash burn, high debt, and execution challenges in bringing new treatments to market, which could pressure the stock if milestones are missed.
SJNK trades at $24.87, up 0.16% on the day, with a bearish technical signal driven by moving averages. Recent news highlights institutional selling, including Cetera Investment Advisers reducing its stake by 9.4% as of July 28, 2026. The ETF maintains regular dividend distributions, with the latest payment scheduled for August 6, 2026.
The outlook is cautious due to technical weakness and negative sentiment from analysts, who cite exhausted tailwinds in high-yield bonds. Risks include interest rate sensitivity and credit spread volatility. Investors should weigh the steady income against potential capital depreciation in a rising rate environment.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BridgeBio Pharma Inc
BridgeBio Pharma Inc is involved in identifying advance transformative medicines to treat patients who suffer from Mendelian diseases, which are diseases that arise from defects in a single gene, and cancers with clear genetic drivers. Its product pipeline categories include Mendelian, Genetic Dermatology, Oncology, and Gene therapy.
Read more on BBIO →About State Street SPDR Bloomberg Shrt Trm Hg Yld Bd ETF
SJNK invests in U.S. dollar-denominated high-yield corporate bonds with short-term maturities (under five years). It offers higher yields than investment-grade funds but with less interest rate sensitivity than longer-term junk bond ETFs.
Read more on SJNK →
